The short version of MC1R fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-27. Anything still debated is marked as such rather than presented as settled.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
== As controlled drug == Thebaine is controlled under international law, is listed as a Class A drug under the Misuse of Drugs Act 1971 in the United Kingdom, is controlled as an analog of a Schedule II drug per the Analog Act in the United States, and is controlled with its derivatives and salts, as a Schedule I substance of the Controlled Drugs and Substances Act in Canada. The 2013 US Drug Enforcement Administration (DEA) aggregate manufacturing quota for thebaine (ACSCN 9333) was unchanged from the previous year at 145 metric tons.
== Bilingual status == Under the University College Galway Act, 1929 (which came into effect on 17 December 1929), the university was given special statutory responsibility with respect of the use of the Irish language as a working language of the university. The Act of 1929 provided that when recruiting a person to work for the university, a person competent in the Irish language must be appointed to the position unless no such person with the necessary competence to carry out the role could be found among the candidates for the position. As a result, every president appointed to the university thereafter was fluent in Irish. The university's governing authority complained that this requirement limited the pool of potential candidates for the office of president (in particular, candidates from overseas). As a result, the Act was amended in 2006 to replace the requirement for fluency in the Irish language amongst staff and management with a commitment to provide for education through the Irish language. In 2016, the university amended its recruitment criteria to allow for the possibility of a non-Irish-speaking president. In August 2025, a non-Irish-speaking president was appointed to the university for the first time since the appointment of Alexander Anderson in 1899.
Protein synthesis, as any other of the 20 proteinogenic amino acids Lipid synthesis, especially by cancer cells. Regulation of acid-base balance in the kidney by producing ammonium Cellular energy, as a source, next to glucose Nitrogen donation for many anabolic processes, including the synthesis of purines Carbon donation, as a source, refilling the citric acid cycle Nontoxic transporter of ammonia in the blood circulation.
Sources: en.wikipedia.org
Their KOR agonism may be involved in ibogaine's putative antiaddictive effects in the setting of opioid dependence. Analogues with strongly enhanced KOR agonist potency such as oxa-noribogaine, GM-3009, and 4-allyl-6-oxa-noribogainalog have been developed. GM-3009 is under development by Gilgamesh Pharmaceuticals for the treatment of opioid-related disorders. The selective KOR agonist and benzomorphan MR-2034 ((–)-MR-2033) led to the initial discovery in the 1980s that KOR agonists produce hallucinogenic and dysphoric effects as opposed to these effects being mediated by concomitant sigma receptor agonism.
This approach was first termed by Amartya Sen, where he mainly focused on the objectives of the approach rather than the aim for those objectives which entail resources, technological processes, and economic arrangement. The central human capabilities include life, bodily health, bodily integrity, sense, emotions, practical reason, affiliation, other species, play, and control over one's environment. This normative framework recognizes that human capabilities are always changing and technology has already played a part in this.
=== Structural and political accounts === From the early 1980s, critical medical anthropology was applied to drug use, shifting attention from cultural meaning to the political and economic structures within which drug use occurs: political systems, economic inequality, and institutional power over social processes. The approach emphasises three themes — self-medication of the distress produced by social inequality and injustice; the social production of suffering, meaning the ill health and hardship concentrated among those with least power; and the political economy of licit and illicit drug markets. On this view, heavy drug use and addiction are consequences of these larger-scale inequalities in power.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
Dry powder is usually held frozen, shielded from light, and kept away from moisture. Desiccant packaging limits hydrolysis during storage. Solutions are typically aliquoted and frozen once, because repeated thawing shortens useful life.